NASDAQ:EFTR

eFFECTOR Therapeutics - EFTR Stock Forecast, Price & News

$0.56

+0.00 (+0.37%)

(As of 09/26/2022 05:19 PM ET)

Add

Compare

Today's Range: $0.54
▼
$0.58
50-Day Range: $0.50
▼
$1.00
52-Week Range: $0.47
▼
$17.99

Volume: 151,310 shs
Average Volume: 435,687 shs
Market Capitalization: $23.42 million

P/E Ratio: 0.74
Dividend Yield: N/A
Price Target: $11.30

eFFECTOR Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 1,695.1% Upside
$10.30 Price Target
Short Interest: Healthy
1.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.76
Based on 2 Articles This Week
Insider Trading: Selling Shares
$200,151 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.65) to ($0.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

406th out of 1,069 stocks

Pharmaceutical Preparations Industry

183rd out of 533 stocks

3.4

Analyst's Opinion

Consensus Rating
eFFECTOR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.30, eFFECTOR Therapeutics has a forecasted upside of 1,695.1% from its current price of $0.57.
Amount of Analyst Coverage
eFFECTOR Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.43% of the float of eFFECTOR Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
eFFECTOR Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in eFFECTOR Therapeutics has recently increased by 21.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
eFFECTOR Therapeutics does not currently pay a dividend.
Dividend Growth
eFFECTOR Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EFTR.

0.7

News and Social Media Coverage

News Sentiment
eFFECTOR Therapeutics has a news sentiment score of -0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for eFFECTOR Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 3 people have searched for EFTR on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added eFFECTOR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, eFFECTOR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,151.00 in company stock.
Percentage Held by Insiders
17.30% of the stock of eFFECTOR Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.92% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for eFFECTOR Therapeutics are expected to decrease in the coming year, from ($0.65) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of eFFECTOR Therapeutics is 0.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.68.
Price to Earnings Ratio vs. Sector
The P/E ratio of eFFECTOR Therapeutics is 0.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.42.
Price to Book Value per Share Ratio
eFFECTOR Therapeutics has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About eFFECTOR Therapeutics (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Stock News Headlines

September 26, 2022 | finance.yahoo.com

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

September 21, 2022 | finance.yahoo.com

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

September 18, 2022 | americanbankingnews.com

eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 3%

September 14, 2022 | nasdaq.com

EFFECTOR Says First Patient Dosed In Second Cohort Of Phase 1b Trial Of Zotatifin For COVID-19

September 14, 2022 | finance.yahoo.com

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

September 6, 2022 | finance.yahoo.com

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 5, 2022 | finance.yahoo.com

eFFECTOR Therapeutics, Inc. (EFTR)

June 30, 2022 | uk.investing.com

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

June 7, 2022 | finance.yahoo.com

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

June 6, 2022 | seekingalpha.com

eFFECTOR Therapeutics down 22% despite positive interim results in solid tumors trial

June 5, 2022 | tmcnet.com

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin

June 5, 2022 | finance.yahoo.com

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

May 26, 2022 | finance.yahoo.com

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

May 16, 2022 | nasdaq.com

Bitcoin Now Buys You the Greatest Amount of eFFECTOR Therapeutics in the Past Year

May 3, 2022 | finance.yahoo.com

How Much Of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Do Institutions Own?

April 4, 2022 | finance.yahoo.com

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

March 18, 2022 | seekingalpha.com

eFFECTOR Therapeutics GAAP EPS of $0.44, revenue of $0.31M

March 17, 2022 | benzinga.com

eFFECTOR Therapeutics's Return On Capital Employed Overview

March 16, 2022 | finance.yahoo.com

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 16, 2022 | finance.yahoo.com

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

February 15, 2022 | finance.yahoo.com

2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit Suisse

February 9, 2022 | finance.yahoo.com

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

January 26, 2022 | benzinga.com

Stifel Downgrades eFFECTOR Therapeutics to Hold, Lowers Price Target to $6.2

January 25, 2022 | markets.businessinsider.com

Analyst Ratings For eFFECTOR Therapeutics

January 24, 2022 | seekingalpha.com

eFFECTOR Therapeutics provides pipeline update; inks up to $50M investment contract

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Company Calendar

Last Earnings: 8/09/2022
Today: 9/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EFTR
CUSIP: N/A
CIK: 1828522
Web: www.locustwalkacquisitioncorp.com
Phone: 415-697-0763
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.30
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +1,900.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.76
Trailing P/E Ratio: 0.74
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $15.80 million
Net Margins: N/A
Pretax Margin: 876.03%
Return on Equity: 176.47%
Return on Assets: 46.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.79
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: $1.43 million
Price / Sales: 16.38
Cash Flow: $0.39 per share
Price / Cash Flow: 1.44
Book Value: $0.43 per share
Price / Book: 1.31

Miscellaneous

Outstanding Shares: 41,453,000
Free Float: 34,282,000
Market Cap: $23.42 million
Optionable: Not Optionable
Beta: 0.46

Key Executives

Dr. Stephen T. Worland Ph.D. (Age 64)
CEO, Pres & Director
Comp: $753.39k

Mr. Michael Byrnes M.B.A. (Age 45)
Chief Financial Officer
Comp: $554.44k

Dr. Premal Patel M.D. (Age 51)
Ph.D., Consultant
Comp: $657.1k

Dr. Siegfried Reich Ph.D. (Age 62)
Co-Founder and Member of Clinical & Scientific Advisory Board

Dr. Davide Ruggero Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

Dr. Kevan M. Shokat Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

Dr. Douglas Warner M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EFTR Stock - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings or view top-rated stocks.
What is eFFECTOR Therapeutics' stock price forecast for 2022?: 4 equities research analysts have issued 12-month price objectives for eFFECTOR Therapeutics' shares. Their EFTR share price forecasts range from $5.00 to $20.00. On average, they predict the company's share price to reach $10.30 in the next year. This suggests a possible upside of 1,772.7% from the stock's current price.
View analysts price targets for EFTR or view top-rated stocks among Wall Street analysts.
How have EFTR shares performed in 2022?: eFFECTOR Therapeutics' stock was trading at $8.28 at the beginning of 2022. Since then, EFTR stock has decreased by 93.4% and is now trading at $0.55.
View the best growth stocks for 2022 here.
How were eFFECTOR Therapeutics' earnings last quarter?: eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) released its earnings results on Tuesday, August, 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $2.01 million for the quarter.

What is eFFECTOR Therapeutics' stock symbol?: eFFECTOR Therapeutics trades on the NASDAQ under the ticker symbol "EFTR."
Who are eFFECTOR Therapeutics' major shareholders?: eFFECTOR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Parallel Advisors LLC (4.09%), Resolute Financial LLC (0.07%), Renaissance Technologies LLC (0.07%) and Callan Capital LLC (0.05%). Insiders that own company stock include Brian M Jr Gallagher, Christopher B Ehrlich, Jonathan D Root, Michael Byrnes, Presidio Management Group X Ll and Stephen T Worland.
View institutional ownership trends.
How do I buy shares of eFFECTOR Therapeutics?: Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is eFFECTOR Therapeutics' stock price today?: One share of EFTR stock can currently be purchased for approximately $0.55.
How much money does eFFECTOR Therapeutics make?: eFFECTOR Therapeutics (NASDAQ:EFTR) has a market capitalization of $22.80 million and generates $1.43 million in revenue each year. The company earns $15.80 million in net income (profit) each year or $0.76 on an earnings per share basis.
How can I contact eFFECTOR Therapeutics?: eFFECTOR Therapeutics' mailing address is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. The official website for the company is www.locustwalkacquisitioncorp.com. The company can be reached via phone at 415-697-0763.

This page (NASDAQ:EFTR) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

eFFECTOR Therapeutics - EFTR Stock Forecast, Price & News

eFFECTOR Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows